泰林生物(300813) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥67,363,245.41, a decrease of 21.84% compared to the same period last year[5] - The net profit attributable to shareholders was ¥1,180,325.54, down 75.06% year-on-year, while the net profit after deducting non-recurring gains and losses was -¥155,169.53, a decrease of 103.36%[5] - The company's basic earnings per share for the period was ¥0.01, down 75.00% year-on-year, while diluted earnings per share were ¥0.00, a decrease of 100.00%[5] - Total operating revenue decreased to ¥213,188,852.61 from ¥242,467,278.88, representing a decline of approximately 12.06% year-over-year[17] - Total operating costs decreased to ¥201,314,970.50 from ¥236,221,850.45, a reduction of about 14.77% year-over-year[17] - Net profit increased to ¥14,523,036.61 from ¥10,599,894.14, marking a growth of approximately 37.25% year-over-year[18] - The total comprehensive income attributable to shareholders increased to ¥14,723,274.72 from ¥11,314,672.20, an increase of about 30.67% year-over-year[18] Cash Flow - The cash flow from operating activities showed a net inflow of ¥14,859,155.99, representing a significant increase of 171.73% compared to the previous year[5] - Operating cash inflow for the current period was 255,549,763.42 CNY, up from 233,795,795.59 CNY in the previous period, representing an increase of approximately 9.4%[19] - Net cash flow from operating activities improved to 14,859,155.99 CNY from a negative 20,714,994.54 CNY in the previous period[19] - Cash inflow from investment activities totaled 763,283,824.00 CNY, compared to 569,235,804.24 CNY in the previous period, marking an increase of approximately 34%[20] - Net cash flow from investment activities was 18,597,586.88 CNY, down from 28,422,441.32 CNY in the previous period[20] - Cash flow from financing activities resulted in a net outflow of 40,384,964.10 CNY, compared to a net inflow of 4,725,027.41 CNY in the previous period[20] - The company received 11,174,000.00 CNY from financing activities, down from 15,645,426.70 CNY in the previous period[20] - Total cash outflow for operating activities was 240,690,607.43 CNY, compared to 254,510,790.13 CNY in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥934,063,765.94, a decrease of 2.69% from the end of the previous year[5] - Total current assets decreased from 632,761,878.52 CNY to 545,192,536.68 CNY, a reduction of approximately 13.78%[15] - Cash and cash equivalents decreased from 264,872,528.62 CNY to 134,971,542.57 CNY, a decline of about 49.0%[15] - Accounts receivable increased from 43,546,552.81 CNY to 49,034,637.68 CNY, an increase of approximately 12.1%[15] - Inventory increased from 144,134,014.09 CNY to 153,639,950.20 CNY, an increase of about 6.0%[15] - Total liabilities increased to ¥143,919,186.72 from ¥139,178,386.25, an increase of approximately 5.30%[16] - The equity attributable to shareholders decreased to ¥790,144,579.22 from ¥820,050,345.31, a decrease of about 3.65%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,437[11] - The largest shareholder, Ye Daling, holds 37.73% of shares, totaling 45,724,000 shares[11] - The second-largest shareholder, Ni Weiju, holds 15.18% of shares, totaling 18,402,400 shares[11] - The company has committed to a share transfer agreement with Ni Weiju, locking in 12.1 million shares for 12 months[12] Other Financial Metrics - The company reported a significant increase in intangible assets, which rose by 153.85% to ¥27,715,686.10, primarily due to land purchases[8] - The company experienced a 245.94% increase in credit impairment losses, amounting to -¥1,457,109.13, due to an increase in accounts receivable[9] - The company reported a financial expense of -¥5,896,688.66, compared to a financial expense of ¥3,361,208.48 in the previous period, reflecting a significant change in financial performance[18] - Research and development expenses remained stable at ¥49,120,227.85 compared to ¥49,454,422.64, indicating a slight decrease of 0.68%[18] - The deferred income tax liabilities decreased to ¥3,225,150.58 from ¥3,393,283.59, a reduction of approximately 4.95%[16] Audit Information - The company did not undergo an audit for the third quarter financial report[21]